Pouria Mashouri

Pouria Mashouri

Auto-generated profile, based on publicly available information

Pouria Mashouri

DATA Team, University Health Network, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in The American Journal of Human Genetics
Verified
Journal Article
Open access
HGHernan D. Gonorazky
Hernan D. Gonorazky
SNSergey Naumenko
Sergey Naumenko
ARArun K. Ramani
Arun K. Ramani
VNViswateja Nelakuditi
Viswateja Nelakuditi
PMPouria Mashouri
Pouria Mashouri
JDJames J. Dowling
James J. Dowling
Gene-panel and whole-exome analyses are now standard methodologies for mutation detection in Mendelian disease. However, the diagnostic yield achieved is at best 50%, leaving the genetic basis for disease unsolved in many individuals. New approaches are thus needed to narrow the diagnostic gap. Whole-genome sequencing is one potential strategy, but it currently has variant-interpretation challenges, particularly for non-coding changes. In this study we focus on transcriptome analysis, specifically total RNA sequencing (RNA-seq), by using monogenetic neuromuscular disorders as proof of principle. We examined a cohort of 25 exome and/or panel "negative" cases and provided genetic resolution in 36% (9/25). Causative mutations were identified in coding and non-coding exons, as well as in intronic regions, and the mutational pathomechanisms included transcriptional repression, exon skipping, and intron inclusion. We address a key barrier of transcriptome-based diagnostics: the need for source material with disease-representative expression patterns. We establish that blood-based RNA-seq is not adequate for neuromuscular diagnostics, whereas myotubes generated by transdifferentiation from an individual's fibroblasts accurately reflect the muscle transcriptome and faithfully reveal disease-causing mutations. Our work confirms that RNA-seq can greatly improve diagnostic yield in genetically unresolved cases of Mendelian disease, defines strengths and challenges of the technology, and demonstrates the suitability of cell models for RNA-based diagnostics. Our data set the stage for development of RNA-seq as a powerful clinical diagnostic tool that can be applied to the large population of individuals with undiagnosed, rare diseases and provide a framework for establishing minimally invasive strategies for doing so.

9 March 2022
Verified
Journal Article
Open access
HDHannah G. Driver
Hannah G. Driver
THTaila Hartley
Taila Hartley
EPE. Magda Price
E. Magda Price
ATAndrei L. Turinsky
Andrei L. Turinsky
OBOrion J. Buske
Orion J. Buske
KBKym M. Boycott
Kym M. Boycott
Despite recent progress in the understanding of the genetic etiologies of rare diseases (RDs), a significant number remain intractable to diagnostic and discovery efforts. Broad data collection and sharing of information among RD researchers is therefore critical. In 2018, the Care4Rare Canada Consortium launched the project C4R-SOLVE, a subaim of which was to collect, harmonize, and share both retrospective and prospective Canadian clinical and multiomic data. Here, we introduce Genomics4RD, an integrated web-accessible platform to share Canadian phenotypic and multiomic data between researchers, both within Canada and internationally, for the purpose of discovering the mechanisms that cause RDs. Genomics4RD has been designed to standardize data collection and processing, and to help users systematically collect, prioritize, and visualize participant information. Data storage, authorization, and access procedures have been developed in collaboration with policy experts and stakeholders to ensure the trusted and secure access of data by external researchers. The breadth and standardization of data offered by Genomics4RD allows researchers to compare candidate disease genes and variants between participants (i.e., matchmaking) for discovery purposes, while facilitating the development of computational approaches for multiomic data analyses and enabling clinical translation efforts for new genetic technologies in the future.

1 June 2020 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
PMPouria Mashouri
Pouria Mashouri
BTBabak Taati
Babak Taati
HQHannah Quirt
Hannah Quirt
AIAndrea Iaboni
Andrea Iaboni

24 May 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
JHJennifer A. Hoang
Jennifer A. Hoang
PMPouria Mashouri
Pouria Mashouri
RDRuixue Dai
Ruixue Dai
MBMay G. Brydges
May G. Brydges
ADAimée Dubeau
Aimée Dubeau
TEThomas Eiwegger
Thomas Eiwegger

20 May 2026 in npj Digital Medicine
Verified
Journal Article
Open access
AWAriana Walji
Ariana Walji
CMCaterina Masino
Caterina Masino
SWStephanie Williams
Stephanie Williams
SGSpencer Gable-Cook
Spencer Gable-Cook
JQJimmy Qiu
Jimmy Qiu
AMAmin Madani
Amin Madani
Recent years have seen a surge in the development of Artificial Intelligence (AI) technologies to enhance intraoperative decision-making and improve patient safety. Yet, real-world evidence on their implementation remains limited. This study evaluated the impact of AI deployment in the operating room across key implementation domains-usability, cost, and carbon footprint-using cloud and edge-based infrastructures. Twenty-three end-users (surgeons, residents, fellows, operating room nurses) from a multi-site teaching hospital in Canada participated in system usability testing, assessed with validated scales and open-ended feedback. Cost and carbon footprint were assessed based on operational metrics. Results showed greater deployment task completion with Cloud but increased physical strain, carbon emissions, and operational costs compared to Edge after 396 h of use. Despite similar usability ratings, participants suggested improvements to the Cloud setup and both systems' interface. Findings provide evidence-based recommendations toward the implementation of sustainable, user-centered AI systems in surgical practice.